Loading...
•
Dec 31, 2024
Viatris Q4 2024 Earnings Report
Viatris reported a decline in Q4 2024 revenue and profitability, with efforts to stabilize operations and streamline costs.
Key Takeaways
Viatris posted Q4 2024 revenue of $3.52 billion, reflecting an 8% decline year-over-year. The company reported a GAAP net loss of $516.5 million and adjusted EPS of $0.54. While the Greater China segment showed positive growth, other geographic regions and product categories experienced declines.
Total revenue for Q4 2024 was $3.52 billion, down 8% year-over-year.
GAAP net loss of $516.5 million, with an adjusted EPS of $0.54.
Brands revenue declined 10% year-over-year to $2.17 billion.
Free cash flow of $342.3 million, down 15% compared to Q4 2023.
Viatris
Viatris
Viatris Revenue by Segment
Viatris Revenue by Geographic Location
Revenue by Segment
Brands Revenue
CapyFin.comRevenue by Geographic Location
Developed Markets Revenue
CapyFin.comEmerging Markets Revenue
CapyFin.comJANZ Revenue
CapyFin.comGreater China Revenue
CapyFin.com Forward Guidance
Viatris expects 2025 revenue between $13.5 billion and $14 billion, with a focus on capital returns and operational efficiency.
Positive Outlook
- Revenue guidance of $13.5 billion to $14 billion for 2025.
- Anticipates $450 million to $550 million in new product revenues.
- Plans for $500 million to $650 million in share repurchases.
- Continued focus on reducing leverage and improving financial flexibility.
- Potential pipeline milestones for late-stage drug candidates.
Challenges Ahead
- Indore facility regulatory issues expected to impact 2025 revenue by $500 million.
- Adjusted EBITDA impact of $385 million due to regulatory actions.
- Ongoing net losses despite cost-cutting efforts.
- Declines in key geographic segments, except for Greater China.
- Increased competitive pressures affecting branded product sales.